ArticleVaccine2025

Projecting maximum potential demand for nirsevimab to protect eligible US infants and young children against respiratory syncytial virus in the 2024/2025 season.

Scott W Olesen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.